Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Vomiting 1Neoplasms, Germ Cell and Embryonal 1Nausea 1Glioma 1

Interventions

Dexamethasone 29Aprepitant 24Palonosetron 20Ondansetron 20Calcium Dobesilate 13Olanzapine 12Granisetron 11Therapeutics 7fosaprepitant 6Doxorubicin 6Cyclophosphamide 6dexamethasone acetate 5netupitant 4Vincristine 4dolasetron 3Yoga 3Tropisetron 3Surveys and Questionnaires 3Psychiatric Rehabilitation 3Prochlorperazine 3Metoclopramide 3Lorazepam 3Dronabinol 3Acupressure 3peppermint oil 2netupitant, palosentron drug combination 2ginger extract 2dexamethasone 21-phosphate 2Sugars 2Rituximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Nausea × rolapitant × Clear all
NCT02991456 2023-07-11

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

Duke University

Phase 2 Completed
48 enrolled 25 charts
CNS

Glioma, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡